Clinical Trials Browser

Attenuated familial adenomatous polyposis, Duodenal Neoplasms, Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT07283705 2026-03-18

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

Phase 2 Suspended

60 enrolled

Gastrointestinal

Phase 2 Study

NCT07011550 2026-03-11

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

Phase 2 Suspended

7 enrolled

Gastrointestinal

Microsatellite-stable Colorectal Cancer

NCT07071961 2026-02-17

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

Phase 2 Suspended

16 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05062889 2026-02-03

ERASE-CRC

Phase 2 Suspended

477 enrolled

Gastrointestinal

Colonic Neoplasms

NCT05358704 2025-12-04

Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer

Phase 2 Suspended

38 enrolled

Gastrointestinal

Rectal Neoplasms

NCT05620771 2025-10-20

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Phase 2 Suspended

84 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05494697 2025-10-14

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

Phase 2 Suspended

90 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05797870 2025-08-08

Lip-Re2

Phase 2 Suspended

16 enrolled

Gastrointestinal

Hepatocellular Carcinoma Non-resectable

NCT05591534 2025-08-01

ICUREC

Phase 2 Suspended

31 enrolled

Gastrointestinal

Rectal Neoplasms

NCT05571293 2025-07-30

NEST-1

Phase 2 Suspended

36 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Colorectal Neoplasms

NCT06728657 2025-06-18

TORCH-G

Phase 2 Suspended

68 enrolled

Gastrointestinal

Stomach Adenocarcinoma

NCT03722680 2025-04-23

RILUZOX-01

Phase 2 Suspended

80 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05375708 2025-03-28

SIRIUS

Phase 2 Suspended

93 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04840186 2024-11-12

EXCALIBUR3

Phase 2 Suspended

62 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06199882 2024-10-15

SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

Phase 2 Suspended

34 enrolled

Gastrointestinal

Biliary Tract Carcinoma

NCT04090463 2024-05-07

PancFORT

Phase 2 Suspended

100 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03779100 2019-01-28

Lenvatinib Plus PD-1 Antibody for Unresectable ICC

Phase 2 Suspended

25 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT01342653 2016-11-21

HIPEC

Phase 2 Suspended

50 enrolled

GastrointestinalGynecologic

Carcinoma, Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms

NCT01723306 2016-06-14

Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas

Phase 2 Suspended

48 enrolled

GastrointestinalThoracic

Lung Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT00609310 2012-02-03

Dietary Bioflavonoid Supplementation for the Prevention of Neoplasia Recurrence

Phase 2 Suspended

382 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT00568529 2010-05-26

Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer

Phase 2 Suspended

30 enrolled

Gastrointestinal

Stomach Neoplasms

NCT00536770 2007-11-06

A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer

Phase 2 Suspended

132 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT00048529 2005-06-24

Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus

Phase 2 Suspended

70 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

Clinical Trials

Testing Obeticholic Acid for Familial Adenomatous Polyposis

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

ERASE-CRC

Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

Lip-Re2

ICUREC

NEST-1

TORCH-G

RILUZOX-01

SIRIUS

EXCALIBUR3

SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

PancFORT

Lenvatinib Plus PD-1 Antibody for Unresectable ICC

HIPEC

Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas

Dietary Bioflavonoid Supplementation for the Prevention of Neoplasia Recurrence

Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer

A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer

Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus